Literature DB >> 31486593

Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients.

Christopher E Dandoy1,2, Tammy Kelley3, Aditya H Gaur4, Rajaram Nagarajan1,2, Kathy Demmel1, Priscila Badia Alonso1,2, Terri Guinipero5, Stephanie Savelli6, Hana Hakim4, Angie Owings4, Kasiani Myers1,2, Victor Aquino7, Carol Oldridge8, Mary Lynn Rae9, Katharine Schjodt10, Tracie Kilcrease11, Michelle Scurlock12, Ann M Marshburn13, Margaret Hill14, Mary Langevin15, Jennifer Lee15, Raven Cooksey16, Amir Mian8, Shelby Eckles7, Justin Ferrell1,2, Javier El-Bietar1,2, Adam Nelson1,2, Brian Turpin1,2, Frederick S Huang17, John Lawlor18, Megan Esporas18, Adam Lane1,2, Jeffrey Hord6, Amy L Billett19.   

Abstract

BACKGROUND: Pediatric hematology/oncology (PHO) patients receiving therapy or undergoing hematopoietic stem cell transplantation (HSCT) often require a central line and are at risk for bloodstream infections (BSI). There are limited data describing outcomes of BSI in PHO and HSCT patients.
METHODS: This is a multicenter (n = 17) retrospective analysis of outcomes of patients who developed a BSI. Centers involved participated in a quality improvement collaborative referred to as the Childhood Cancer and Blood Disorder Network within the Children's Hospital Association. The main outcome measures were all-cause mortality at 3, 10, and 30 days after positive culture date; transfer to the intensive care unit (ICU) within 48 hours of positive culture; and central line removal within seven days of the positive blood culture.
RESULTS: Nine hundred fifty-seven BSI were included in the analysis. Three hundred fifty-four BSI (37%) were associated with at least one adverse outcome. All-cause mortality was 1% (n = 9), 3% (n = 26), and 6% (n = 57) at 3, 10, and 30 days after BSI, respectively. In the 165 BSI (17%) associated with admission to the ICU, the median ICU stay was four days (IQR 2-10). Twenty-one percent of all infections (n = 203) were associated with central line removal within seven days of positive blood culture.
CONCLUSIONS: BSI in PHO and HSCT patients are associated with adverse outcomes. These data will assist in defining the impact of BSI in this population and demonstrate the need for quality improvement and research efforts to decrease them.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  BMT; ICU; Infections; immunocompromised hosts; infections in immunocompromised hosts; outcomes research; pediatric hematology/oncology

Mesh:

Year:  2019        PMID: 31486593     DOI: 10.1002/pbc.27978

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Alcohol-impregnated caps and ambulatory central-line-associated bloodstream infections (CLABSIs): A randomized clinical trial.

Authors:  Aaron M Milstone; Carol Rosenberg; Gayane Yenokyan; Danielle W Koontz; Marlene R Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2020-10-12       Impact factor: 3.254

2.  Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.

Authors:  Christopher E Dandoy; Soyoung Kim; Min Chen; Kwang Woo Ahn; Monica I Ardura; Valerie Brown; Saurabh Chhabra; Miguel Angel Diaz; Christopher Dvorak; Nosha Farhadfar; Aron Flagg; Siddartha Ganguly; Gregory A Hale; Shahrukh K Hashmi; Peiman Hematti; Rodrigo Martino; Taiga Nishihori; Roomi Nusrat; Richard F Olsson; Seth J Rotz; Anthony D Sung; Miguel-Angel Perales; Caroline A Lindemans; Krishna V Komanduri; Marcie L Riches
Journal:  JAMA Netw Open       Date:  2020-01-03

3.  Simulated Pediatric Blood Cultures to Assess the Inactivation of Clinically Relevant Antimicrobial Drug Concentrations in Resin-Containing Bottles.

Authors:  Liliana Giordano; Flora Marzia Liotti; Giulia Menchinelli; Giulia De Angelis; Tiziana D'Inzeo; Grazia Angela Morandotti; Maurizio Sanguinetti; Teresa Spanu; Brunella Posteraro
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

4.  Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation.

Authors:  Christopher J Severyn; Benjamin A Siranosian; Sandra Tian-Jiao Kong; Angel Moreno; Michelle M Li; Nan Chen; Christine N Duncan; Steven P Margossian; Leslie E Lehmann; Shan Sun; Tessa M Andermann; Olga Birbrayer; Sophie Silverstein; Carol G Reynolds; Soomin Kim; Niaz Banaei; Jerome Ritz; Anthony A Fodor; Wendy B London; Ami S Bhatt; Jennifer S Whangbo
Journal:  JCI Insight       Date:  2022-04-08

5.  Levofloxacin Versus Ciprofloxacin-Based Prophylaxis during the Pre-Engraftment Phase in Allogeneic Hematopoietic Stem Cell Transplant Pediatric Recipients: A Single-Center Retrospective Matched Analysis.

Authors:  Alessia G Servidio; Roberto Simeone; Davide Zanon; Egidio Barbi; Natalia Maximova
Journal:  Antibiotics (Basel)       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.